Brief: Medicenna Announces That Initiation Of Mdna11 Phase 1/2 Study Is On Track Update To Be Provided At The Propthink Digital Conference
27/07/2021 15:34
July 27 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA ANNOUNCES THAT INITIATION OF MDNA11 PHASE 1/2
STUDY IS
ON TRACK; UPDATE TO BE PROVIDED AT THE PROPTHINK DIGITAL
CONFERENCE
* MEDICENNA THERAPEUTICS CORP - STUDY TO START ENROLLMENT IN
Q3 OF
2021 IN AUSTRALIA, WITH EXPANSION TO ADDITIONAL SITES IN US, UK
AND CANADA
Source text for Eikon: ID:nGNX3nSTyB
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results